Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was $37.12 for the day, down -0.83% from the previous closing price of $37.43. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 0.59 million shares were traded. RARE stock price reached its highest trading level at $37.85 during the session, while it also had its lowest trading level at $36.47.
Ratios:
Our analysis of RARE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 6.17 whereas as Long-Term Debt/Eq ratio is at 5.70.
On June 06, 2024, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $56 to $67.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.RBC Capital Mkts initiated its Outperform rating on April 22, 2024, with a $77 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 20 ’25 when Sanders Corazon (Corsee) D. sold 2,405 shares for $37.39 per share. The transaction valued at 89,923 led to the insider holds 15,344 shares of the business.
CORAZON D. SANDERS bought 2,405 shares of RARE for $89,923 on Jun 20 ’25. On May 05 ’25, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 520 shares for $39.24 each. As a result, the insider received 20,405 and left with 71,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3538708992 and an Enterprise Value of 3905629184. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.94 while its Price-to-Book (P/B) ratio in mrq is 24.12. Its current Enterprise Value per Revenue stands at 6.612 whereas that against EBITDA is -8.173.
Stock Price History:
The Beta on a monthly basis for RARE is 0.26, which has changed by -0.096836984 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $29.59. The 50-Day Moving Average of the stock is 1.63%, while the 200-Day Moving Average is calculated to be -15.14%.
Shares Statistics:
RARE traded an average of 1.02M shares per day over the past three months and 972730 shares per day over the past ten days. A total of 93.74M shares are outstanding, with a floating share count of 88.38M. Insiders hold about 6.52% of the company’s shares, while institutions hold 95.27% stake in the company. Shares short for RARE as of 1749772800 were 6081072 with a Short Ratio of 5.98, compared to 1747267200 on 5891832. Therefore, it implies a Short% of Shares Outstanding of 6081072 and a Short% of Float of 6.6599995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
